Fenimore Christopher R. — SEC insider filings
SEC reporting owner CIK 1697422. 27 insider filings on record with FilingPulse; latest filed 2026-11-04.
Transaction summary — filings shown
Covers all 27 filings on record, filed 2020-12-11 to 2026-11-04. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 30 legs across 8 filings — 27,140 shares, $23,966,789 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 68.
- Largest priced transaction: sale of 4,576 shares @ $655.00 ($2,997,280) in REGENERON PHARMACEUTICALS, INC., filed 2021-08-24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC. (REGN) | EVP Finance CFO | 27 | — | 30 legs · 27,140 sh · $23,966,789 | 68 |
Insider filings — Fenimore Christopher R.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-04 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 6,000 @ $381.92 · Tax withholding (F): 4,243 @ $950.50 · Gift (G): 15 @ $0 · Option exercise (M): 6,000 (derivative) @ $0 | EDGAR |
| 2026-08-20 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 6,283 @ $381.92 · Tax withholding (F): 4,599 @ $813.47 · Option exercise (M): 6,283 (derivative) @ $0 | EDGAR |
| 2025-12-09 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/award (A): 3,027 @ $0 · Tax withholding (F): 992 @ $712.94 · Grant/award (A): 14,924 (derivative) @ $0 | EDGAR |
| 2024-12-18 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Tax withholding (F): 491 @ $730.81 | EDGAR |
| 2024-12-10 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/award (A): 2,591 @ $0 · Tax withholding (F): 1,140 @ $787 · Grant/award (A): 9,979 (derivative) @ $0 | EDGAR |
| 2024-08-29 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Sale (S): 228 @ $1,204.79 · Sale (S): 766 @ $1,205.44 · Sale (S): 200 @ $1,206.30 · Sale (S): 2,237 @ $1,204.71 · Sale (S): 928 @ $1,205.49 · Sale (S): 450 @ $1,206.15 · +4 more | EDGAR |
| 2024-02-12 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Sale (S): 344 @ $950.49 · Sale (S): 487 @ $951.39 · Sale (S): 1,046 @ $952.62 · Sale (S): 1,342 @ $953.47 · Sale (S): 1,100 @ $954.57 · Sale (S): 600 @ $955 | EDGAR |
| 2024-01-25 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 5,000 @ $555.67 · Tax withholding (F): 3,986 @ $948.50 · Option exercise (M): 5,000 @ $399.66 · Tax withholding (F): 3,583 @ $948.50 · Option exercise (M): 5,000 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-01-04 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 5,000 @ $555.67 · Tax withholding (F): 4,043 @ $912.30 · Option exercise (M): 5,000 @ $399.66 · Tax withholding (F): 3,469 @ $912.30 · Option exercise (M): 5,000 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2023-12-29 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Sale (S): 2,448 @ $856.71 | EDGAR |
| 2023-12-26 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Sale (S): 456 @ $843.79 · Sale (S): 1,224 @ $844.09 · Sale (S): 250 @ $846.27 | EDGAR |
| 2023-12-14 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Tax withholding (F): 2,552 @ $856.71 | EDGAR |
| 2023-12-12 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Tax withholding (F): 474 @ $843.79 · Grant/award (A): 2,370 @ $0 · Tax withholding (F): 1,276 @ $844.09 · Tax withholding (F): 260 @ $844.09 · Grant/award (A): 8,499 (derivative) @ $0 | EDGAR |
| 2023-08-25 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 7,000 @ $399.66 · Tax withholding (F): 5,198 @ $842.66 · Option exercise (M): 7,000 (derivative) @ $0 | EDGAR |
| 2023-03-27 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Sale (S): 2,192 @ $806.47 | EDGAR |
| 2023-02-07 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 5,000 @ $270.43 · Tax withholding (F): 3,286 @ $774.29 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2022-12-20 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/award (A): 1,926 @ $0 · Grant/award (A): 7,111 (derivative) @ $0 | EDGAR |
| 2022-12-13 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Tax withholding (F): 247 @ $753.28 · Gift (G): 871 @ $0 · Gift (G): 436 @ $0 · Gift (G): 435 @ $0 | EDGAR |
| 2022-10-07 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Sale (S): 1,844 @ $749 | EDGAR |
| 2022-10-05 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Sale (S): 3,346 @ $724 | EDGAR |
| 2022-04-11 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 2,450 @ $555.67 · Tax withholding (F): 2,155 @ $736.21 · Option exercise (M): 5,000 @ $270.43 · Tax withholding (F): 3,451 @ $736.21 · Option exercise (M): 5,000 (derivative) @ $0 · Option exercise (M): 2,450 (derivative) @ $0 | EDGAR |
| 2022-04-01 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 2,000 @ $555.67 · Tax withholding (F): 1,797 @ $700.99 · Option exercise (M): 10,000 @ $270.43 · Tax withholding (F): 6,857 @ $700.99 · Option exercise (M): 10,000 (derivative) @ $0 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2021-12-14 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Tax withholding (F): 270 @ $664.34 | EDGAR |
| 2021-12-10 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/award (A): 1,859 @ $0 · Grant/award (A): 7,941 (derivative) @ $0 | EDGAR |
| 2021-08-25 | 4/A | REGENERON PHARMACEUTICALS, INC. (REGN) | Tax withholding (F): 8,719 @ $664.85 | EDGAR |
| 2021-08-24 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 13,500 @ $179.13 · Sale (S): 4,576 @ $655 · Sale (S): 9 @ $659.33 · Sale (S): 23 @ $660.33 · Sale (S): 88 @ $661.89 · Sale (S): 1 @ $662.78 · +3 more | EDGAR |
| 2020-12-11 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/award (A): 969 @ $0 · Grant/award (A): 1,750 @ $0 · Gift (G): 50 @ $0 · Gift (G): 25 @ $0 · Gift (G): 25 @ $0 · Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-12-09 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1697422 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs